Aytu BioPharma, Inc. filed an 8-K on November 16, 2026, disclosing that it entered into an Agreement and Plan of Merger with Rosemont Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary RoseApollo Merger Sub, Inc., providing for the acquisition of Aytu BioPharma through a two-step tender offer and subsequent merger at $2.70 per share in cash.

Key Highlights

  • Offer Price: Purchaser will commence a tender offer to acquire all issued and outstanding shares of Aytu BioPharma common stock at $2.70 per share, net to the seller in cash, without interest, subject to applicable tax withholding.
  • Board Recommendation: The Company's board of directors and a special committee unanimously recommended that stockholders accept the offer and tender their shares.
  • Minimum Tender Condition: Consummation of the offer requires that validly tendered and not withdrawn shares, together with shares beneficially owned by Parent, Purchaser, and their wholly owned subsidiaries, represent a majority of shares outstanding at the time of consummation.
  • No Financing Condition: According to the filing, "Consummation of the Offer is not subject to a financing condition."
  • Warrant Condition: No greater than 15% of Company Warrants, measured by the number of underlying shares, may remain outstanding without being exercised prior to the Expiration Date, with related shares validly tendered, or terminated pursuant to applicable agreements.
  • Equity Awards Treatment: Outstanding Company Options will be accelerated and cancelled, with holders receiving a cash payment equal to the number of underlying shares multiplied by the excess of the Merger Consideration over the applicable exercise price; options at or above the Merger Consideration will be cancelled for no consideration.
  • Merger Mechanics: The subsequent merger is to be effected under Section 251(h) of the Delaware General Corporation Law, without a stockholder meeting or vote, following the Acceptance Time.

Aytu BioPharma Merger Agreement: Tender Offer Structure and Key Conditions

According to the filing, Aytu BioPharma, Inc. (NASDAQ:AYTU) entered into the Merger Agreement on November 16, 2026, with Rosemont Pharmaceuticals Holdings, Inc. as Parent and RoseApollo Merger Sub, Inc. as Purchaser. The filing describes a two-step transaction: Purchaser will launch a tender offer for all outstanding shares of Aytu BioPharma common stock, par value $0.0001 per share, at a price of $2.70 per share in cash, and upon satisfying the conditions set forth in the Merger Agreement, Purchaser will then merge with and into the Company, with Aytu BioPharma surviving as a wholly owned subsidiary of Parent.

The filing states that the tender offer must commence no later than ten business days after the date of the Merger Agreement and, unless extended, will expire one minute after 11:59 p.m., New York City time, on the twentieth day following and including commencement of the offer. Beyond the majority-tender threshold, the filing identifies additional closing conditions including the accuracy of the Company's representations and warranties, material compliance with covenants, the absence of a Company material adverse effect, receipt of required third-party consents, Parent's receipt of customary payoff letters for outstanding Payoff Debt, and the warrant condition described above.

The filing further discloses that at the Effective Time, Company Restricted Shares will have vesting restrictions and forfeiture requirements terminated and will be treated as shares in accordance with the Merger Agreement. The Company Equity Plans and Company ESPP are to be terminated at the Effective Time. The Company is also required to use reasonable best efforts to cause each Company Warrant holder not party to a Support Agreement to either exercise its warrants or enter into a Company Warrant Termination Agreement before the applicable deadline.

What Was Disclosed

Aytu BioPharma disclosed entry into a merger agreement providing for a cash tender offer at $2.70 per share followed by a back-end merger, with the board unanimously recommending that stockholders tender their shares, and no financing condition attached to the offer.